HologicHOLX
About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Employees: 7,063
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
3% less first-time investments, than exits
New positions opened: 100 | Existing positions closed: 103
9% less call options, than puts
Call options by funds: $19.2M | Put options by funds: $21.1M
2.0% less ownership
Funds ownership: 99.4% [Q4 2024] → 97.4% (-2.0%) [Q1 2025]
3% less funds holding
Funds holding: 706 [Q4 2024] → 688 (-18) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 229 | Existing positions reduced: 275
17% less capital invested
Capital invested by funds: $16.3B [Q4 2024] → $13.5B (-$2.77B) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Citigroup Patrick Donnelly | 22%upside $80 | Buy Upgraded | 9 Jul 2025 |
Evercore ISI Group Vijay Kumar | 3%upside $68 | In-Line Maintained | 8 Jul 2025 |
Stephens & Co. Mason Carrico | 7%upside $70 | Overweight Maintained | 13 May 2025 |
Morgan Stanley Tejas Savant | 1%downside $65 | Equal-Weight Maintained | 5 May 2025 |
RBC Capital Conor McNamara | 7%upside $70 | Sector Perform Maintained | 2 May 2025 |
Financial journalist opinion
Based on 12 articles about HOLX published over the past 30 days
